Original scientific paper

GENETIC POLYMORPHISMS IN DOPAMINERGIC SYSTEM AND TREATMENT-RESISTANT SCHIZOPHRENIA

Tea Terzić orcid.org/0000-0002-4917-4891 ; University Psychiatric Clinic Ljubljana, Ljubljana, Slovenia
Matej Kastelic ; Pharmacogenetics Laboratory, Institute of Biochemistry, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
Vita Dolžan ; Pharmacogenetics Laboratory, Institute of Biochemistry, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
Blanka Kores Plesničar ; University Psychiatric Clinic Ljubljana, Ljubljana, Slovenia

Abstract

Background: Dopaminergic system plays an important role in antipsychotic response. Functional single nucleotide
polymorphisms (SNPs) can change dopamine receptor expression or dopamine disposition and thus influence response to antipsychotic
treatment.
Subjects and methods: 138 schizophrenia patients were stratified in the treatment-resistant and treatment-responsive group.
Control group consisted of 94 healthy blood donors. All subjects were genotyped for the following SNPs: DRD1 (rs4532, rs5326),
DRD2 (rs1801028, rs1799732), DRD3 (rs6280) and COMT (rs165815, rs4680). Association between the genotypes and clinical
symptoms were tested using ANCOVA with current antipsychotic dose as a confounder. Differences in allele frequencies between
treatment-responsive and treatment-resistant schizophrenic patients were assessed using χ2 tests.
Results: No statistically significant associations were observed between any of the investigated genotypes and clinical scores and
occurrence of the treatment-resistant schizophrenia.
Conclusions: Genetic variability in dopaminergic system does not have a major role in clinical symptoms and occurrence of
treatment-resistant schizophrenia among Slovenian patients.

Keywords

dopamine; COMT - single nucleotide polymorphism; treatment-resistant schizophrenia; antipsychotic

Hrčak ID:

175257

URI

https://hrcak.srce.hr/175257

Publication date:

7.6.2016.

Visits: 1.092 *